Talabostat (PT-100) T-cell independent anti-tumor activity cooperates with pemetrexed and erlotinib in A549 non-small cell lung cancer (NSCLC) xenograft model.

被引：0
|
作者：
Adams, S [1 ]
Surman, M [1 ]
Jones, B [1 ]
机构：
[1] Point Therapeut Inc, Boston, MA USA
来源：
CLINICAL CANCER RESEARCH | 2005年 / 11卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：9157S / 9157S
页数：1
相关论文
共 50 条
  • [21] The combination of antitumor drugs, exemestane and erlotinib, induced resistance mechanism in H358 and A549 non-small cell lung cancer (NSCLC) cell lines
    Kritikou, Ismini
    Giannopoulou, Efstathia
    Koutras, Angelos K.
    Labropoulou, Vassiliki T.
    Kalofonos, Haralabos P.
    PHARMACEUTICAL BIOLOGY, 2014, 52 (04) : 444 - 452
  • [22] Augmented antitumor effects of erlotinib and cabozantinib on A549 non-small cell lung cancer: In vitro and in vivo studies
    Alhazzani, Khalid
    Alsahli, Meshal
    Alanazi, Ahmed Z.
    Algahtani, Mohammad
    Alenezi, Ahmad A.
    Alhoshani, Ali
    Alqinyah, Mohammed
    Alhamed, Abdullah S.
    Alhosaini, Khaled
    SAUDI PHARMACEUTICAL JOURNAL, 2023, 31 (10)
  • [23] Anti-tumor activity of autologous GM-CSF gene-modified tumor cell vaccines (GVAX®) in non-small cell lung cancer (NSCLC)
    Hege, K
    Sterman, D
    Jablons, D
    Smith, J
    Fox, B
    Woo, EY
    Lin, A
    Borellini, F
    Jalali, S
    Maples, P
    Nemunaitis, J
    CANCER GENE THERAPY, 2001, 8 : S24 - S24
  • [24] Anti-cancer mechanisms of lovastatin in A549 human non-small cell lung cancer cells
    Wang, Jie-Yu
    FASEB JOURNAL, 2017, 31
  • [25] Neutrophil depletion enhances the anti-tumor activity of CAR-T cells in an autochthonous model of non-small cell lung cancer
    Ortiz-Espinosa, Sergio
    Srivastava, Shivani
    CANCER IMMUNOLOGY RESEARCH, 2023, 11 (12)
  • [26] Encapsulated paclitaxel nanoparticles exhibit enhanced anti-tumor efficacy in A549 non-small lung cancer cells
    Huang, Guojin
    Zang, Bao
    Wang, Xiaowei
    Liu, Gang
    Zhao, Jianqiang
    ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2015, 47 (12) : 981 - 987
  • [27] Synergistic anti-tumor effect of the combination of amrubicin and erlotinib in non-small cell lung cancer with wild type EGFR
    Otani, Sakiko
    Sasaki, Jiichiro
    Masuda, Kuniko
    Okamoto, Kazuya
    Namubu, Akiko
    Matsumoto, Toshihide
    Tanaka, Masumi
    Ishihara, Mikiko
    Nakahara, Yashiro
    Fukui, Tomoya
    Igawa, Satoshi
    Masuda, Noriyuki
    CANCER RESEARCH, 2016, 76
  • [28] Inhibition Effects of Metformin and Pemetrexed on the Proliferation, Apoptosis and Migration Capabilities of Non-small Cell Lung Cancer Cell Line A549 in vitro
    Zhang, Yan
    CHEST, 2016, 149 (04) : 305A - 305A
  • [29] Activity and safety of gefitinib and erlotinib in metastatic non-small cell lung cancer (NSCLC): A comparative analysis
    Franchina, T.
    Adamo, B.
    Caristi, N.
    Chiofalo, G.
    Toscano, G.
    Colonese, F.
    Denaro, N.
    Ricciardi, G. R.
    Russo, A.
    Adamo, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [30] Cost-effectiveness of erlotinib vs. docetaxel or pemetrexed in the treatment of refractory non-small cell lung cancer (NSCLC)
    Carlson, J.
    Oestreicher, N.
    Lubeck, D. P.
    Ramsey, S. D.
    Veenstra, D. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345